Showing results (691-700 of 1,609) with videos related to

Sort By:
Pageof 161
JAMA Oncology|November 6, 2025
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional ProphylaxisRohtesh S Mehta, Rodney A Sparapani, Christopher G Kanakry, et al.
JAMA Oncology|October 23, 2025
Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer TreatmentAna Barac, Jiling Chou, Nawar Shara, et al.
JAMA Oncology|October 16, 2025
Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical TrialNikita Sushentsev, Anne Y Warren, Richard Colling, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
JAMA Oncology|September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled TrialDickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
JAMA Oncology|September 25, 2025
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical TrialPeter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, et al.
JAMA Oncology|August 14, 2025
Childhood Cancer Survivorship Globally: A Systematic ReviewMelissa Martos, Nicholas George, Farina E Arreguín-González, et al.
JAMA Oncology|July 31, 2025
Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical TrialZhonghua Tao, Jian Zhang, Qiufan Zheng, et al.
JAMA Oncology|August 19, 2021
Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With CancerMichael B Foote, James Robert White, Justin Jee, et al.
JAMA Oncology|August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical TrialSumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
Pageof 161